Request Legal Help Now - Free


Clarinex Shareholders

Newark, NJ: (Jan-14-08) A shareholders' derivative suit was brought against Schering-Plough Corp., alleging that the company was responsible for the Food and Drug Administration's delay in approving of Clarinex because of continued manufacturing deficiencies at plants in New Jersey and Puerto Rico, despite several warning letters from the agency. The suit stated that Clarinex was slated to fill the void created by the imminent loss of patent protection for Claritin, the company's blockbuster allergy drug. The plaintiffs alleged that the delay caused a drop in stock prices and harmed the company's reputation.

In a recent development, a federal judge approved a settlement in the shareholders' derivative suit, awarding no damages, but instead granting a $9.5 million fee to plaintiffs counsel and a company pledge to reform its governance. [LAW.COM: SHAREHOLDERS SETTLEMENT]

Legal Help

If you have a similar problem and would like to be contacted by a lawyer at no cost or obligation, please click the link below.
Published on Jan-15-08


Fields marked * are mandatory. Please read our comment guidelines before posting.


Note: Your name will be published with your comment.

*Email Address:

Your email will only be used if a response is needed.
*Your Comment:

Are you the defendant or a subject matter expert on this topic with an opposing viewpoint? We'd love to hear your comments here as well, or if you'd like to contact us for an interview please submit your details here.

Request Legal Help Now! - Free